^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) + Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
Published date:
03/17/2023
Excerpt:
Thirty patients with pathologically confirmed advanced ICC received intravenous gemcitabine (1 g/m2) on Days 1 and 8 and oxaliplatin (85 mg/m2) Q3W for six cycles along with intravenous toripalimab (240 mg) Q3W and oral lenvatinib (8 mg) once daily for one year....Patients (21/30) with DNA damage response (DDR)-related gene mutations showed a higher ORR…
Secondary therapy:
gemcitabine + oxaliplatin
DOI:
https://doi.org/10.1038/s41392-023-01317-7
Trial ID:
Source:
Title:
56P - Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial
Published date:
09/14/2020
Excerpt:
The combination of toripalimab, lenvatinib with Gemox chemotherapy was tolerable and showed promising ORR in patients with advanced ICC. ORR was significantly associated with PD-L1 expression and DNA damage repair (DDR)-related mutations in tumor samples.
Secondary therapy:
GemOx
Trial ID:
